JAK2‐related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor‐activating mutation

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as gefitinib and erlotinib, are effective for non‐small cell lung cancer with activating EGFR mutations. However, even in patients with an initial dramatic response to such a drug, acquired resistance develops after 6–12 months...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Sci
Asıl Yazarlar: Harada, Daijiro, Takigawa, Nagio, Ochi, Nobuaki, Ninomiya, Takashi, Yasugi, Masayuki, Kubo, Toshio, Takeda, Hiromasa, Ichihara, Eiki, Ohashi, Kadoaki, Takata, Saburo, Tanimoto, Mitsune, Kiura, Katsuyuki
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2012
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7659254/
https://ncbi.nlm.nih.gov/pubmed/22712764
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2012.02363.x
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller